Abstract：
BACKGROUND: Botulinum toxin type A (BTX-A), produced by the gram-positive anaerobic bacterium Clostridium botulinum, acts by cleaving synaptosome-associated protein-25 (SNAP-25), an essential component of the presynaptic neuronal membrane that is necessary for fusion with the membrane proteins of neurotransmitter-containing vesicles. Recent studies have highlighted the efficacy of BTX-A in treating chronic pain conditions, including lower back pain, chronic neck pain, neuropathic pain, and trigeminal neuralgia, particularly when patients are unresponsive to traditional painkillers. This review focuses on the analgesic effects of BTX-A in various chronic pain conditions, with a particular emphasis on the orofacial region.
CONCLUSIONS: This review focuses on the mechanisms by which BTX-A induces analgesia in patients with inflammatory and temporomandibular joint pain. This review also highlights the fact that BTX-A can effectively manage neuropathic pain and trigeminal neuralgia, which are difficult-to-treat chronic pain conditions. Herein, we present a comprehensive assessment of the central analgesic effects of BTX-A and a discussion of its various applications in clinical dental practice.
CONCLUSIONS: BTX-A is an approved treatment option for various chronic pain conditions. Although there is evidence of axonal transport of BTX-A from peripheral to central endings in motor neurons, the precise mechanism underlying its pain-modulating effects remains unclear. This review discusses the evidence supporting the effectiveness of BTX-A in controlling chronic pain conditions in the orofacial region. BTX-A is a promising therapeutic agent for treating pain conditions that do not respond to conventional analgesics.
CONCLUSIONS: This review focuses on the mechanisms by which BTX-A induces analgesia in patients with inflammatory and temporomandibular joint pain. This review also highlights the fact that BTX-A can effectively manage neuropathic pain and trigeminal neuralgia, which are difficult-to-treat chronic pain conditions. Herein, we present a comprehensive assessment of the central analgesic effects of BTX-A and a discussion of its various applications in clinical dental practice.
CONCLUSIONS: BTX-A is an approved treatment option for various chronic pain conditions. Although there is evidence of axonal transport of BTX-A from peripheral to central endings in motor neurons, the precise mechanism underlying its pain-modulating effects remains unclear. This review discusses the evidence supporting the effectiveness of BTX-A in controlling chronic pain conditions in the orofacial region. BTX-A is a promising therapeutic agent for treating pain conditions that do not respond to conventional analgesics.
摘要：
背景：A型肉毒杆菌毒素（BTX-A），由革兰氏阳性厌氧细菌肉毒梭状芽孢杆菌产生，通过切割突触体相关蛋白25（SNAP-25）起作用，突触前神经元膜的必需成分，是与含神经递质的囊泡的膜蛋白融合所必需的。最近的研究强调了BTX-A治疗慢性疼痛的疗效，包括下背部疼痛,慢性颈部疼痛，神经性疼痛,三叉神经痛,特别是当患者对传统止痛药无反应时。本文综述了BTX-A在各种慢性疼痛中的镇痛作用。特别强调口面区域。
结论：本综述主要关注BTX-A在炎性和颞下颌关节痛患者中诱导镇痛的机制。这篇综述还强调了BTX-A可以有效治疗神经性疼痛和三叉神经痛的事实。这是难以治疗的慢性疼痛病症。在这里，我们对BTX-A的中枢镇痛效果进行了全面评估，并讨论了其在临床牙科实践中的各种应用。
结论：BTX-A是各种慢性疼痛病症的批准治疗选择。尽管有证据表明BTX-A在运动神经元中从外周末梢轴突转运到中枢,其疼痛调节作用的确切机制尚不清楚.这篇评论讨论了支持BTX-A在控制口面区域慢性疼痛状况方面的有效性的证据。BTX-A是用于治疗对常规镇痛药无反应的疼痛病症的有前途的治疗剂。
结论：本综述主要关注BTX-A在炎性和颞下颌关节痛患者中诱导镇痛的机制。这篇综述还强调了BTX-A可以有效治疗神经性疼痛和三叉神经痛的事实。这是难以治疗的慢性疼痛病症。在这里，我们对BTX-A的中枢镇痛效果进行了全面评估，并讨论了其在临床牙科实践中的各种应用。
结论：BTX-A是各种慢性疼痛病症的批准治疗选择。尽管有证据表明BTX-A在运动神经元中从外周末梢轴突转运到中枢,其疼痛调节作用的确切机制尚不清楚.这篇评论讨论了支持BTX-A在控制口面区域慢性疼痛状况方面的有效性的证据。BTX-A是用于治疗对常规镇痛药无反应的疼痛病症的有前途的治疗剂。
